PI3K/Akt/mTOR Signaling
The PI3K/Akt/mTOR signaling pathway is a key regulator in growth, survival, cell cycle proliferation, protein synthesis and glucose metabolism. Growth factors, hormones, and cytokines can activate this pathway by binding their cognate receptor tyrosine kinase (RTK), cytokine receptor, or GPCR, resulting in the activation of lipid kinase PI3K which produces PIP3 at the plasma membrane.
The binding of PIP3 translocates Akt to cell membranes, enables Akt activation through phosphorylation at Thr308 mediated by phosphoinositide dependent kinase 1 (PDK1). In addition, Akt is phosphorylated at Ser473 by the mTOR-rictor complex, mTORC2. PTEN is a negative regulator of Akt signaling that reverses the function of PI3K by removing 3’-phosphate groups. Akt activity is also negatively regulated by the phosphatases PP2A and PHLPP. Akt propagates its signal to affect DNA transcription, cell cycle and apoptosis. Akt can activate mTOR directly by phosphorylation or indirectly, by phosphorylation and inactivation of mTOR inhibitor TSC2 and PRAS40. Together these mechanisms stimulate cell growth and G1 cell cycle progression through signaling via p70 S6 Kinase and inhibition of 4E-BP1. Defects in PI3K/AKT/mTOR signaling are implicated in cancer, diabetes and cardiovascular disease etc.
- C4638 NSC 210902Summary: CK2 inhibitor
- C4783 UCN-01Summary: inhibitor of Akt, protein kinase C, PDK1 and cyclin-dependent kinases
- C5012 GSK2269557Summary: inhibitor of PI3Kδ
- C5053 KP372-1Summary: specific Akt inhibitor
- B7875 Adenosine 5-monophosphateSummary: 5'-AMP-activated protein kinase
- C5216 NG,NG-dimethyl-L-Arginine (hydrochloride)1 CitationSummary: endogenous nitric oxide synthase inhibitor
- B1536 AZD10801 CitationTarget: GSK-3Summary: GSK3βinhibitor
- B1047 GDC-0032Target: PI3KSummary: PI3Kα inhibitor
- B1212 ImegliminSummary: Antidiabetic agent
- B1067 Imeglimin hydrochlorideSummary: Antidiabetic agent